<DOC>
	<DOCNO>NCT00001994</DOCNO>
	<brief_summary>To evaluate safety tolerance atovaquone ( 566C80 ) AIDS patient central nervous system ( CNS ) toxoplasmosis . To evaluate efficacy 566C80 acute treatment suppression CNS toxoplasmosis AIDS patient fail tolerate conventional therapy .</brief_summary>
	<brief_title>A Pilot Study 566C80 Salvage Treatment Toxoplasmic Encephalitis Patients Infected With Human Immunodeficiency Virus ( HIV ) Who Have Failed Are Intolerant Pyrimethamine-Sulfadiazine</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Toxoplasmosis</mesh_term>
	<mesh_term>Toxoplasmosis , Cerebral</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<mesh_term>Sulfadiazine</mesh_term>
	<criteria>Inclusion Criteria Patients must follow : Presumptive diagnosis AIDS . Cerebral toxoplasmosis . Expected survival least four week without therapy . Willing able give inform consent . Prior Medication : Allowed : Pyrimethaminesulfonamide . Clindamycinsulfonamide . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Significant emotional disorder psychosis . Evidence significant malabsorption , ileus significant emesis entry would inhibit drug absorption . Other known central nervous system lesion lymphoma , tuberculoma , cryptococcoma , active neurosyphilis . Unwilling unable take 566C80 meal , enteral supplement ( eg : Ensure Plus ) pulverize form nasogastric tube . Active drug alcohol abuse sufficient investigator 's opinion prevent compliance study regimen . Concurrent Medication : Excluded : Drugs potential antitoxoplasmosis activity include sulfone , sulfonamide , trimethoprim , pyrimethamine clindamycin acute therapy phase trial . First three week treatment : Retrovir ( zidovudine ) investigational agent include antiretroviral agent ( eg : ddI , ddC ) . Patients follow exclude : Significant emotional disorder psychosis . Evidence significant malabsorption , ileus significant emesis entry would inhibit drug absorption . Other known central nervous system lesion lymphoma , tuberculoma , cryptococcoma , active neurosyphilis . Unwilling unable take 566C80 meal , enteral supplement ( eg : Ensure Plus ) pulverize form nasogastric tube . Active drug alcohol abuse sufficient investigator 's opinion prevent compliance study regimen . Active drug alcohol abuse sufficient investigator 's opinion prevent compliance study regimen .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1992</verification_date>
	<keyword>Toxoplasmosis</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Naphthoquinones</keyword>
	<keyword>Encephalitis</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>